Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00688688 · ClinicalTrials.gov registry record · Phase 3
Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase 3 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,792
- Enrollment target
NCT00688688 is a Phase 3 study that has completed, run by Astellas Pharma. The registered enrollment target is 2,792 participants.
The verdict
NCT00688688, a Phase 3 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,792 participants
- Enrollment target
Study Summary
The study is intended to test the safety, tolerability, efficacy of two doses of long term once daily (qd) treatment of Mirabegron in patients with symptoms of overactive bladder and secondly to compare these with active comparator.
Interventions
- DRUG Mirabegron
- DRUG Tolterodine
- DRUG Placebo to Mirabegron
- DRUG Placebo to Tolterodine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,792 participants |
| Start Date | 2008-04-25 |
| Est. Completion | 2010-05-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00688688
The ClinicalTrials.gov registry entry for NCT00688688 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,792 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Mirabegron is the first listed.
NCT00688688 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00688688 about?
NCT00688688 is a clinical study titled "Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder". The study is intended to test the safety, tolerability, efficacy of two doses of long term once daily (qd) treatment of Mirabegron in patients with symptoms of overactive bladder and secondly to compare these with active comparator.
What is the current status of trial NCT00688688?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,792 participants. The study started on 2008-04-25. Estimated completion is 2010-05-06.
What interventions are being tested in trial NCT00688688?
The interventions under investigation include: Mirabegron (DRUG), Tolterodine (DRUG), Placebo to Mirabegron (DRUG), Placebo to Tolterodine (DRUG).
Who is sponsoring clinical trial NCT00688688?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.